May Daher

Featured in: Favicon

nature.com Favicon

frontiersin.org Favicon

biomedcentral.com Favicon

aacrjournals.org Favicon

biorxiv.org Favicon

onlinelibrary.wiley.com + 2 more

Articles

"Multiplexed engineering and precision gene editing in cellular immunot" by Alexander Biederstädt, Gohar Shahwar Manzar et al.

Aug 22, 2024 | digitalcommons.library.tmc.edu | Alexander Biederstädt |Gohar Manzar |May Daher |Gohar Shahwar

The advent of cellular immunotherapy in the clinic has entirely redrawn the treatment landscape for a growing number of human cancers. Genetically reprogrammed immune cells, including chimeric antigen receptor (CAR)-modified immune effector cells as well as T cell receptor (TCR) therapy, have demonstrated remarkable responses across different hard-to-treat patient populations.
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial - Nature Medicine

Jan 18, 2024 | nature.com | Hind Rafei |May Daher |Vakul Mohanty |Merve Dede |Peter F Thall |Roland Bassett | +6 more

AbstractThere is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19+ B cell malignancies. The primary objectives were safety and efficacy, defined as day 30 overall response (OR).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →